uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

2 years ago

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to…

Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics

2 years ago

Proceeds will support lead precision oncology program into the clinic and advance earlier stage pipelineAtavistik Bio is discovering transformative precision…

Appointment of Chief Business Officer

2 years ago

        19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals…

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

2 years ago

CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder…

Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference

2 years ago

Tuesday, January 9, 2024, at 3:45 pm Pacific TimePONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts,…

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

2 years ago

PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on…

SweetWater Brewing Announces 27th Anniversary Party Concert Lineup

2 years ago

SweetWater Brewing Company's Official 27th Anniversary Party Poster Join SweetWater for their 27th Anniversary happening on February 17th, 2024! EarthGang…

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

2 years ago

– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life…

Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

2 years ago

TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage…

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

2 years ago

SUNNYVALE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the…